Czechia· CZ-0238363

EMGALITY

A galcanezumab product containing galcanezumab, registered in Czechia by Eli Lilly Nederland B.V., Utrecht. The same ATC class is registered in 13 of our 19 countries.

ATC N02CD02

Checked against SÚKL (Czech Republic) on

Informational only — not a medical device.

SOURCE REGISTER · CZSÚKL (Czech Republic)normalisedEMGALITYATCN02CD02REGISTER NO.CZ-0238363PACKS LISTED0CHECKEDSeptember 28, 2026

Where it is registered

Galcanezumab is registered in 13 of 19 countries.

Countries holding a registration under ATC N02CD02 (galcanezumab), each read from that country’s own register.

  • This record: Czechia, from SÚKL (Czech Republic)
  • 9 of them publish a price we can compare per daily dose

Galcanezumab · ATC N02CD02

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

SÚKL (Czech Republic)
Active substance
GALCANEZUMAB
Manufacturer
Eli Lilly Nederland B.V., Utrecht
Country
Czechia (CZ)
ATC code
N02CD02
ATC class
Galcanezumab
Defined daily dose
4 mg, P
Reimbursed
Not published by this register
Source register
SÚKL (Czech Republic)
Last checked
September 28, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b984e383-94ba-425d-bba3-39350d347eb5
GET /v1/drugs/b984e383-94ba-425d-bba3-39350d347eb5?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "INJ SOL PEP",
  "source": "sukl",
  "strength": "120MG",
  "pack_size": "3X1ML",
  "substance": "GALCANEZUMAB",
  "cz_kod_sukl": "0238363",
  "product_type": "BT",
  "substance_codes": "20987",
  "registration_state": "R",
  "registration_number": "EU/1/18/1330/002"
}

See everything about galcanezumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.